Endocrinologic syndromes part II

Patients who have serum calcium levels higher than thirteen mg/dl
or who exhibit symptoms connected to hypercalcemia sometimes require
treatment. goals of treatment ought to embrace hydration, inhibition
of bone resorption and/or promotion of calcium excretion,
and treatment of the underlying malignancy. 115
as a result of hypercalcemic patients are typically dehydrated,
rehydration has become the moststay of treatment. vigorous
hydration with isotonic saline (200 to four
hundred ml/hr) are often used
for many hours to revive intravascular volume and glomerular
filtration to promote calcium excretion. 116 care should be
taken within the patient with cardiovascular compromise or renal
insufficiency to avoid volume overload. in cases of renal failure,
dialysis could ought to be employed. diuretics ought to be
used judiciously once rehydration could be achieved. thiazide diuretics
ought to be avoided as a result of they will increase calcium
resorption within the distal tubule. furosemide is that the diuretic of
alternative and may promote calcium excretion by interfering with
calcium reabsorption within the ascending limb of henle’s loop.
diuretics ought to be primarily used to balance fluid intake and
output. the use of saline hydration and forced diuresis for
treatment of hypercalcemia is not recommended. along
with hydration, a pharmaceutical agent that helps decrease
bone resorption ought to be employed.
the bisphosphonates are the safest and most effective agents
used for the treatment of hypercalcemia. these compounds
are structural analogues of pyrophosphate and by binding to
hydroxyapatite are potent inhibitors of bone crystal dissolution
and osteoclast reabsorption. pamidronate and zoledronate
are the medicine most commonly used for the treatment of
hypercalcemia. during a randomized trial, zoledronate (4 and eight mg)
proved to be statistically superior to pamidronate (90 mg) in
that it yielded a additional rapid and sustained decrease in serum
calcium. 117 the recommended dose of zoledronic acid is four mg
by a 15-minute infusion. the medicine have an acceptable safety
profile however ought to be administered with caution in patients
with renal insufficiency.
gallium nitrate could be a potent inhibitor of bone resorption via
inhibition of an atpase-dependent pump within the osteoclast. 118
gallium nitrate is sometimes administered at a dose of 100 to
200 mg/m a pair of /day by continuous infusion for up to five days,
creating it somewhat inconvenient. urine output has to be
maintained throughout administration and nephrotoxic drugs
ought to be avoided as a result of a possible for renal toxicity.
calcitonin (4 to eight iu/kg intramuscularly or subcutaneously
each twelve hours) exerts its hypocalcemic impact by inhibiting
bone resorption and promoting calcium excretion. 119 the
main advantage is that it's a rapid onset of action and may
be used in patients notwithstanding they need renal insufficiency. the
main disadvantage of the drug is that the hypocalcemic effect
is weak and transient. plicamycin (mithramycin) could be an antineoplastic
agent that's toxic to osteoclasts. 120 its use is currently
limited secondary to lack of availability and potential adverse
aspect effects. corticosteroids are useful agents in patients whose
diseases are typically treated with these medicine (i. e., hematologic
malignancies, breast cancer). steroids don't seem to be notably useful
in lung cancer–related hypercalcemia.
ultimately, successful treatment of the malignancy controls
hypercalcemia. this goal is an elementicularly troublesome within the
case of advanced lung cancer. no effective oral agents are available
for maintenance of a desired serum calcium level. patients
who have continued issues with symptomatic hypercalcemia
could require intermittent treatment with a bisphosphonate,
that will simply be given as an outpatient infusion.